NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

The gravy train you refer to is probably the observation LP has accumulated so many shares with more complete knowledge than retail. She did it via debt financing.

If she had to face a CC, she’d almost certainly say the decision to unblind is out of her hands, and really falls to the SAB. The SAB might state they were awaiting 36 months from last randomized patient because the blended mOS for methylated MGMT was 34.7 months as of the interim March 2017 data cutoff, and NICE is willing to consider/highlight subgroups as particularly suited for therapy. To me, after this data collection, there is no reason to continue the blind.

(The whole bigger fatter curve/tail mantra is illogical, because no particular year of enrollees impacts the survival curve different than other years.)